title: Patient satisfaction with medication for gastroesophageal reflux disease: a systematic review.
abstract: BACKGROUND
  Patient satisfaction is increasingly regarded as an important aspect of measuring treatment success in individuals with gastroesophageal reflux disease (GERD).
  
  
  OBJECTIVE
  To review how satisfied patients with GERD are with their medication, and to analyze the usefulness of patient satisfaction as a clinical end point by comparing it with symptom improvement.
  
  
  METHODS
  Systematic searches of the PubMed and EMBASE databases identified clinical trials and patient surveys published between 1966 and 2009.
  
  
  RESULTS
  Twelve trials reported that 56% to 100% of patients were 'satisfied' or 'very satisfied' with proton pump inhibitor (PPI) treatment for GERD. Patient satisfaction levels were higher for PPIs than other GERD medications in two trials. The sample-size-weighted average proportion of patients 'satisfied' with their PPI after four weeks of treatment in trials was 93% (95% CI 87% to 99%), with 73% (95% CI 62% to 83%) being 'very satisfied'. In four surveys, the average proportion of patients 'satisfied' with their PPI treatment was 82% (95% CI 73% to 90%) and 62% (95% CI 48% to 75%) were 'very satisfied'. Seven trials found a positive association between patient satisfaction and symptom improvement, and two surveys between satisfaction and improved health-related quality of life. Three trials found that continuous treatment yielded higher rates of satisfaction than on-demand therapy.
  
  
  CONCLUSIONS
  More than one-half of patients were satisfied with their PPI medication in trials, and more patients were satisfied with PPIs than other medication types. An association between patient satisfaction and symptom resolution was found, suggesting that patient satisfaction is a useful end point for evaluating GERD treatment success.
authors.affiliation: University of Alberta, Edmonton, Alberta, Canada. vanzanten@ualberta.ca
authors.forename: Sander Jo
authors.initials: SJ
authors.lastname: van Zanten
authors.forename: Catherine
authors.initials: C
authors.lastname: Henderson
authors.forename: Nesta
authors.initials: N
authors.lastname: Hughes
mesh_terms: D000863:Antacids / Q000008:administration & dosage / Q000009:adverse effects; D005764:Gastroesophageal Reflux / Q000150:complications / Q000188:drug therapy* / Q000503:physiopathology; D006356:Heartburn / Q000188:drug therapy* / Q000209:etiology / Q000503:physiopathology; D006801:Humans; D057045:Laryngopharyngeal Reflux / Q000188:drug therapy* / Q000209:etiology / Q000503:physiopathology; D010358:Patient Participation / Q000706:statistics & numerical data; D017060:Patient Satisfaction / Q000706:statistics & numerical data*; D054328:Proton Pump Inhibitors / Q000008:administration & dosage / Q000009:adverse effects; D011788:Quality of Life; D012107:Research Design; D012720:Severity of Illness Index; D018434:Sickness Impact Profile; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D000863:Antacids; D054328:Proton Pump Inhibitors